Ken Griffin Autolus Therapeutics PLC Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 2,800 shares of AUTL stock, worth $7,839. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,800

Previous 11,700 76.07%

Holding current value

$7,839

Previous $40,000 75.0%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.38 - $4.69 $752,996 - $1.04 Million	-222,780 Reduced 42.37%	303,008 $1.1 Million
Q2 2024 Aug 14, 2024	SELL	$3.33 - $5.68 $535,104 - $912,730	-160,692 Reduced 23.41%	525,788 $1.83 Million
Q1 2024 May 15, 2024	BUY	$5.39 - $7.29 $3.49 Million - $4.71 Million	646,715 Added 1626.34%	686,480 $4.38 Million
Q4 2023 Feb 14, 2024	BUY	$2.13 - $6.63 $84,699 - $263,641	39,765 New	39,765 $256,000
Q2 2023 Aug 14, 2023	SELL	$1.64 - $3.21 $2.26 Million - $4.43 Million	-1,379,531 Reduced 88.13%	185,815 $442,000
Q1 2023 May 15, 2023	SELL	$1.75 - $2.25 $370,567 - $476,444	-211,753 Reduced 11.92%	1,565,346 $2.88 Million
Q4 2022 Feb 14, 2023	BUY	$1.74 - $3.27 $1.1 Million - $2.07 Million	634,494 Added 55.53%	1,777,099 $3.38 Million
Q3 2022 Nov 14, 2022	SELL	$2.04 - $3.76 $2.06 Million - $3.8 Million	-1,011,052 Reduced 46.95%	1,142,605 $2.45 Million
Q2 2022 Aug 15, 2022	SELL	$2.04 - $4.68 $2.77 Million - $6.36 Million	-1,358,856 Reduced 38.69%	2,153,657 $6.1 Million
Q1 2022 May 16, 2022	BUY	$3.52 - $5.46 $6.39 Million - $9.91 Million	1,814,570 Added 106.87%	3,512,513 $14.6 Million
Q4 2021 Feb 14, 2022	SELL	$5.1 - $7.0 $3.59 Million - $4.93 Million	-704,891 Reduced 29.34%	1,697,943 $8.81 Million
Q3 2021 Nov 15, 2021	SELL	$5.32 - $7.37 $1.91 Million - $2.65 Million	-359,920 Reduced 13.03%	2,402,834 $15.7 Million
Q2 2021 Aug 16, 2021	BUY	$4.78 - $7.96 $13 Million - $21.7 Million	2,721,085 Added 6530.24%	2,762,754 $18.3 Million
Q1 2021 May 17, 2021	BUY	$5.49 - $9.36 $124,408 - $212,106	22,661 Added 119.22%	41,669 $239,000
Q4 2020 Feb 16, 2021	BUY	$8.13 - $12.79 $45,853 - $72,135	5,640 Added 42.19%	19,008 $170,000
Q3 2020 Nov 16, 2020	SELL	$11.64 - $16.3 $6.59 Million - $9.23 Million	-565,976 Reduced 97.69%	13,368 $156,000
Q2 2020 Aug 14, 2020	SELL	$5.38 - $16.14 $12,696 - $38,090	-2,360 Reduced 0.41%	579,344 $9.29 Million
Q1 2020 May 15, 2020	BUY	$4.2 - $13.0 $2.39 Million - $7.41 Million	570,163 Added 4940.33%	581,704 $3.49 Million
Q4 2019 Feb 14, 2020	SELL	$11.13 - $16.28 $664,950 - $972,632	-59,744 Reduced 83.81%	11,541 $152,000
Q2 2019 Aug 14, 2019	BUY	$15.1 - $31.25 $1.08 Million - $2.23 Million	71,285 New	71,285 $1.15 Million

Others Institutions Holding AUTL

# of Institutions

104

Shares Held

163M

Call Options Held

2.8K

Put Options Held

13.4K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $255M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account